查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
血浆分馏市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年：按产品、方法、应用、最终用户、地理细分、竞争
市场调查报告书
商品编码
1255246

血浆分馏市场 - 全球行业规模、份额、趋势、机会和预测，2018-2028 年：按产品、方法、应用、最终用户、地理细分、竞争

Plasma Fractionation Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Product, By Method, By Application, By End User, By Region, and Competition
出版日期: | 出版商: TechSci Research | 英文 113 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

在预测期内，全球血浆分离市场预计将出现令人瞩目的增长。

这是由于慢性病在所有年龄段的患病率都在增加，包括免疫紊乱和危重疾病，以及对用于治疗慢性病的免疫球蛋白的需求不断增加。 此外，血液和呼吸系统疾病患病率的增加，以及疾病治疗技术的进步，显着增加了世界不同地区对血浆分离的需求。 此外，预计到 2028 年，全球容易患各种慢性病的老年人口不断增加，也将进一步增加对血浆分馏的需求，并推动市场增长。 此外，全球对使用血浆分馏诊断慢性病的好处的认识不断提高，预计也将在预测期内进一步推动血浆分馏市场。 此外，与免疫球蛋白相关的研究和开发活动的增加预计将进一步增加对牙齿轮廓的需求。 根据 Statista 的数据，截至 2022 年，约 51% 的 Bernard-Soulier 综合征患者为女性，49% 为男性。

免疫缺陷患病率上升

血液学和免疫学疾病的发病率上升，白蛋白和免疫球蛋白等重要血浆产品的超适应症使用是预测期内推动市场增长的主要因素。 同样，在医学领域越来越多地使用免疫球蛋白和 alpha-1-抗胰蛋白□作为血浆组分也是推动市场增长的一个因素。 同样，对血浆相关疗法日益增长的需求对于治疗新兴疾病也很重要。 近年来，蛋白□抑製剂（如 ALPHA-1-抗胰蛋白□蛋白）在治疗肺病和肝病中的使用越来越多，预计在预测期内市场将实现有利增长。 例如，根据阿尔茨海默病协会 2021 年 3 月的报告，美国约有 620 万 65 岁及以上的人与阿尔茨海默病相关的痴呆症并存。

新技术开发

领先的公司投资于各种产生积极结果的治疗方法。 製造商正在关注 IgA、纤溶□和铜蓝蛋白等新疗法。 预计这将在预测期内带来有利的增长。 医疗保健行业的快速变化以及持续的技术创新预计将加速北美等发展中国家对血浆分离的需求。 2019 年，全球约有 195,263 人被诊断患有血友病，80,302 人患有血管性血友病。

近期发展

  • 例如，2021 年 3 月，根据 WHO 基本药物标准清单并包括一些血浆衍生医药产品 (PDMP)，以满足卫生系统的基本要求。它将其标识为药物被认为是最有效和安全的，并为在低收入和中等收入国家增加 PDMP 的供应提供了最佳指导方针。
  • 例如，2020 4 月，CSL Behring & Takeda Pharmaceutical Co., Ltd. 宣布 Biotest、BPL、LFB 和 Octapharma 开发可有效治疗 COVID- 19.与合作
  • 例如，2019 年 4 月，为了长期帮助血友病患者，血浆衍生疗法供应商 Grifols International SA 为血友病患者提供了凝血因子药物（1 亿国际单位）病人的治疗。

可用的自定义

根据市场数据，TechSci Research 根据公司的具体需求提供定制服务。 该报告可以定制为：

公司信息

  • 对其他市场参与者（最多 5 家公司）进行深入分析和概况分析

内容

第 1 章概述

  • 市场定义
  • 市场范围
    • 目标市场
    • 研究目标年份
    • 主要市场细分

第二章研究方法论

  • 调查目的
  • 基线调查方法
  • 主要行业合作伙伴
  • 主要协会和次要信息
  • 调查方法
  • 数据三角测量和验证
  • 假设和限制

第 3 章执行摘要

  • 市场概览
  • 主要市场细分概述
  • 主要市场参与者概览
  • 主要地区/国家概览
  • 市场驱动因素、挑战和趋势

第 4 章 VOC（客户之声）

第 5 章全球血浆分馏市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 副产品（白蛋白、免疫球蛋白、凝血因子、蛋白□抑製剂等）
    • 按方法（离心、深层过滤、层析等）
    • 按应用（神经学、血液学、肿瘤学、免疫学等）
    • 由最终用户（医院/诊所、学术/研究机构等）
    • 按地区
    • 按公司分类（2022 年）
  • 市场地图
    • 按产品分类
    • 通过方法
    • 通过使用
    • 最终用户
    • 按地区

第 6 章北美血浆分馏市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按产品分类
    • 通过方法
    • 通过使用
    • 最终用户
    • 按国家
  • 北美：国家/地区分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲血浆分馏市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按产品分类
    • 通过方法
    • 通过使用
    • 最终用户
    • 按国家
  • 欧洲：国家分析
    • 法国
    • 德国
    • 英国
    • 意大利
    • 西班牙

第 8 章亚太地区血浆分馏市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按产品分类
    • 通过方法
    • 通过使用
    • 最终用户
    • 按国家
  • 亚太地区：国家/地区分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳大利亚

第 9 章南美血浆分馏市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按产品分类
    • 通过方法
    • 通过使用
    • 最终用户
    • 按国家
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章中东和非洲血浆分馏市场展望

  • 市场规模和预测
    • 按数量
  • 市场份额和预测
    • 按产品分类
    • 通过方法
    • 通过使用
    • 最终用户
    • 按国家
  • MEA：国家分析
    • 南非血浆分馏
    • 沙特阿拉伯血浆分离
    • 阿联酋血浆分馏
    • 土耳其血浆分馏
    • 埃及血浆分离

第 11 章市场动态

  • 司机
  • 任务

第12章市场趋势与发展

  • 近期趋势
  • M&A（併购）
  • 产品公告

第13章竞争格局

  • Grifols S.A.
  • Octapharma AG
  • Intas Pharmaceuticals Ltd
  • LFB S.A.
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Biotest AG
  • Kedrion S.p.A
  • Bio Products Laboratory Ltd.'
  • Bharat Serums and Vaccines Limited

第14章 战略建议

简介目录
Product Code: 5091

The Global Plasma Fractionation Market is anticipated to witness impressive growth during the forecast period. This can be ascribed to the growing prevalence of chronic diseases among all age groups, such as immunological disorders and grave diseases, along with increasing demand for immunoglobulins for the treatment of chronic diseases. Additionally, the growing prevalence of blood and respiratory disorders due to and growing advancement in technology to cure diseases has significantly increased the demand for plasma fractionation across different parts of the globe. Additionally, the growing geriatric population across the globe, which is susceptible to different kinds of chronic diseases, is further expected to increase the demand for plasma fractionation, thereby fuelling market growth through 2028. Besides, growing awareness about the advantages of using plasma fractions for the diagnosis of chronic diseases across the globe is further expected to support the plasma fractionation market during the forecast period. Furthermore, increasing research and development activities related to immunoglobulin are further expected to increase the demand for dental contouring. According to Statista, as of 2022, around 51 percent of patients with Bernard Soulier syndrome were female, while 49 percent were male.

Growing Prevalence of Immunodeficiency disorder

The increasing incidence of blood and immune disorders and off-label usage of critical plasma products like albumins and immunoglobulins is the main factors that will boost the market growth during the forecast period. Similarly, the rising use of immunoglobulins and alpha-1-antitrypsin in the medical sector as a plasma fraction will propel the growth of the market. Similarly, increasing demand for plasma-related therapies is important for the treatment of new diseases. In the present years, usage of protease inhibitors like alpha-1-antitrypsin protein is increased for the treatment of lung diseases and hepatic diseases; this, in turn, is expected to create lucrative growth for the market in the forecast period. For instance, according to the March 2021 report of the Alzheimer's Association, approximately 6.2 million people of age 65 years and more are living with Alzheimer's-related dementia in the United States.

Development of New Technologies

Major players are investing in different therapies that will produce reliable results. Manufacturers are focusing on new therapies such as IgA, Plasmin, and Ceruloplasmin. This, in turn, is expected to create lucrative growth in the forecast period. A rapid change in the healthcare sector, along with continuous technological innovation, shall accelerate demand for plasma fractionation in developing countries like North America. In 2019, there were around 195,263 people worldwide who had been diagnosed with hemophilia and 80,302 who had been diagnosed with von Willebrand disease.

Market Segmentation

The global plasma fractionation market can be segmented by product, method, application, end-user, and by region. Based on product, the market can be segmented into Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, and Others. Based on the method, the market can be differentiated into Centrifugation, Depth Filtration, Chromatography, and Others. Based on application, the market can be grouped into Neurology, Hematology, Oncology, Immunology, and Others. Based on end users, the market can be segmented into Hospitals & Clinics, Academic & Research Institutes, and Others. Regionally, North America dominated the market among Asia Pacific, Europe, Middle East & Africa, and South America. Among the different countries, the United States dominated the global plasma fractionation market on account of the growing demand for new therapies for the treatment of chronic diseases in the country.

Market Players

Grifols S.A., Octapharma AG, Intas Pharmaceuticals Ltd, LFB S.A., Takeda Pharmaceutical Company Limited, CSL Limited, Biotest AG, Kedrion S.p.A, Bio Products Laboratory Ltd.', Bharat Serums and Vaccines Limited are some of the leading players operating in the Global Plasma Fractionation Market.

Recent Developments

  • For instance, in March 2021, according to the WHO Model List of essential medicines includes several plasma-derived medicinal products (PDMPs), identifying them as drugs thought to be the most efficient and secure for addressing the essential requirements in a health system and provide the best guidelines on increased supply of PDMPs in low & middle-income countries
  • For instance, in April 2020, to create a viable plasma-derived medication for treating COVID-19, CSL Behring & Takeda Pharmaceutical Company Ltd. collaborated with Biotest, BPL, LFB, and Octapharma.
  • For instance, in April 2019, under a long-term initiative to support people with hemophilia, Grifols International SA, a supplier of plasma-derived therapeutics, provided blood clotting factor medications (100 million international units) for the treatment of hemophilic patients.

Report Scope

In this report, global plasma fractionation market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Plasma Fractionation Market, By Product:

  • Albumin
  • Immunoglobulins
  • Coagulation Factors
  • Protease Inhibitors
  • Others

Plasma Fractionation Market, By Method:

  • Centrifugation
  • Depth Filtration
  • Chromatography
  • Others

Plasma Fractionation Market, By Application:

  • Neurology
  • Hematology
  • Oncology
  • Immunology
  • Others

Plasma Fractionation Market, By End User:

  • Hospitals & Clinics
  • Academic & Research Institutes
  • Others

Plasma Fractionation Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • United Kingdom
    • Italy
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Global Plasma Fractionation Market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasma Fractionation Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Albumin, Immunoglobulins, Coagulation Factors, Protease Inhibitors, Others)
    • 5.2.2. By Method (Centrifugation, Depth Filtration, Chromatography, Others)
    • 5.2.3. By Application (Neurology, Hematology, Oncology, Immunology, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Academic & Research Institutes, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2022)
  • 5.3. Market Map
    • 5.3.1. By Product
    • 5.3.2. By Method
    • 5.3.3. By Application
    • 5.3.4. By End User
    • 5.3.5. By Region

6. North America Plasma Fractionation Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Method
    • 6.2.3. By Application
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Plasma Fractionation Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Method
        • 6.3.1.2.3. By Application
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Plasma Fractionation Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Method
        • 6.3.2.2.3. By Application
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Plasma Fractionation Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Method
        • 6.3.3.2.3. By Application
        • 6.3.3.2.4. By End User

7. Europe Plasma Fractionation Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Method
    • 7.2.3. By Application
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Plasma Fractionation Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Application
        • 7.3.1.2.4. By End User
    • 7.3.2. Germany Plasma Fractionation Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Application
        • 7.3.2.2.4. By End User
    • 7.3.3. United Kingdom Plasma Fractionation Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Application
        • 7.3.3.2.4. By End User
    • 7.3.4. Italy Plasma Fractionation Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Application
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Plasma Fractionation Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Application
        • 7.3.5.2.4. By End User

8. Asia-Pacific Plasma Fractionation Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Method
    • 8.2.3. By Application
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Plasma Fractionation Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Application
        • 8.3.1.2.4. By End User
    • 8.3.2. India Plasma Fractionation Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Application
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Plasma Fractionation Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Application
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Plasma Fractionation Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Application
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Plasma Fractionation Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Application
        • 8.3.5.2.4. By End User

9. South America Plasma Fractionation Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Method
    • 9.2.3. By Application
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Plasma Fractionation Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Application
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Plasma Fractionation Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Application
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Plasma Fractionation Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Application
        • 9.3.3.2.4. By End User

10. Middle East and Africa Plasma Fractionation Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Method
    • 10.2.3. By Application
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Plasma Fractionation Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Application
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Plasma Fractionation Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Application
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Plasma Fractionation Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Application
        • 10.3.3.2.4. By End User
    • 10.3.4. Turkey Plasma Fractionation Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Product
        • 10.3.4.2.2. By Method
        • 10.3.4.2.3. By Application
        • 10.3.4.2.4. By End User
    • 10.3.5. Egypt Plasma Fractionation Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Product
        • 10.3.5.2.2. By Method
        • 10.3.5.2.3. By Application
        • 10.3.5.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Competitive Landscape

  • 13.1. Business Overview
  • 13.2. Product Offerings
  • 13.3. Recent Developments
  • 13.4. Financials (As Reported)
  • 13.5. Key Personnel
  • 13.6. SWOT Analysis
    • 13.6.1. Grifols S.A.
    • 13.6.2. Octapharma AG
    • 13.6.3. Intas Pharmaceuticals Ltd
    • 13.6.4. LFB S.A.
    • 13.6.5. Takeda Pharmaceutical Company Limited
    • 13.6.6. CSL Limited
    • 13.6.7. Biotest AG
    • 13.6.8. Kedrion S.p.A
    • 13.6.9. Bio Products Laboratory Ltd.'
    • 13.6.10. Bharat Serums and Vaccines Limited

14. Strategic Recommendations